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ABSTRACT
To determine the suitability of serum endocan (ESM-1) levels for diagnosing 
and monitoring renal cell carcinoma (RCC), we measure serum ESM-1 levels in 56 
RCC patients who had undergone radical or partial nephrectomies and 56 age- and 
sex-matched healthy kidney donors. Measurements were made before and 1 month 
and 3 months after surgery. The areas under the curve (AUCs) were determined 
from receiver operating characteristic (ROC) analyses. RCC patients had higher mean 
serum ESM-1 levels than control subjects (0.59  ±  0.07 vs. 0.52  ±  0.08 ng/mL, 
P < 0.001), with an AUC of 0.721 (95% CI: 0.628–0.817). In patients with tumors 
larger than 2 cm (n = 40) and those with clear-cell histology (n = 44), the AUCs for 
ESM-1 were 0.771 and 0.721, respectively. In control subjects, serum ESM-1 levels 
were higher in older (>50 years) individuals (P < 0.001). Among the study cohort, 
the AUCs for ESM-1 were 0.813 in individuals 50 years of age or younger (n = 55) 
and 0.637 in individuals older than 50 years (n = 57). In RCC patients, serum ESM-1 
levels were reduced 1 month (P = 0.047) and 3 months (P = 0.009) after surgery. 
These results suggest serum ESM-1 can serve as a serologic biomarker for diagnosing 
and monitoring RCC, particularly in patients younger than 50 years. 
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INTRODUCTION
Renal cell carcinoma (RCC) is the most common 
malignant tumor in the kidney [1]. Although most RCC 
cases are diagnosed at an early stage, approximately 40% 
of RCC patients have locally advanced or metastatic 
disease [2]. The early detection of RCC is critical, because 
the cancer-specific survival rate drops from 66%–96% 
for patients with localized RCC to only 12%–36% for 
patients with locally advanced disease [3]. For patients 
with early detected small renal masses, treatment via a 
nephron sparing technique decreases the risk of chronic 
kidney disease and cardiovascular events [4, 5]. Thus, 
the identification of a biomarker for early stage disease 
ensures favorable patient outcomes.
Endocan, or endothelial cell-specific molecule-1 
(ESM-1), is a soluble 50-kDa dermatan sulfate proteoglycan 
expressed by the vascular endothelium [6]. ESM-1 
is overexpressed in obesity, during sepsis, and under 
inflammatory conditions, as well as in malignant tumors [7], 
and ESM-1 is associated with cardiovascular disease [8, 9]. 
In RCC tumors, which are typically hypervascular, ESM-
1 is upregulated by angiogenic factors, such as vascular 
endothelial growth factor (VEGF) and platelet-derived 
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growth factor (PDGF) [10]. A transcriptional profile of RCC 
revealed that ESM-1 is overexpressed in tissue samples of 
RCC [11]. The results from a study of a small number of 
patients by Leroy et al. [12] suggested that serum ESM-1 
levels might serve as biomarkers in RCC. In this study, we 
prospectively enrolled patients with and without RCC and 
measured serum levels of ESM-1 before and after surgery 
to evaluate the potential of ESM-1 levels in diagnosing and 
monitoring RCC.
RESULTS
Patient characteristics are summarized in Table 1. 
Of the 56 patients with RCC, 43 (76.8%) had T1a disease 
and 44 (78.6%) had clear-cell RCC. Although the control 
group was matched according to age and sex, patients in 
the RCC group were significantly older than those in the 
control group (P = 0.027). In the control group, the mean 
serum ESM-1 level did not vary according to sex (0.53 
±  0.08 ng/mL in male patients vs. 0.52  ±  0.77 ng/mL in 
female patients, P = 0.764) but was higher in older (>50 
years) participants than in participants who were younger 
(≤50 years) (0.56  ±  0.06 ng/mL vs. 0.49  ±  0.08 ng/mL, 
P = 0.001). In the RCC group, the mean serum ESM-1 
levels were not different between patients with clear-cell 
RCC and non–clear-cell RCC. In patients with clear-cell 
RCC, the serum ESM-1 levels were significantly higher 
in patients with large tumors and higher stages. However, 
no statistically significant differences were seen among 
patients in the entire RCC group (Table 2).
Patients with RCC had higher serum ESM-1 levels 
than control group participants (0.59  ±  0.07 mg/mL 
vs. 0.52  ±  0.08 ng/mL, P < 0.001) (Figure 1A). The 
area under the curve (AUC) of receiver operating 
characteristic (ROC) for ESM-1 level was 0.721 (95% 
CI: 0.628–0.817) (Figure 1B). With a cutoff value of 
0.568 ng/mL (calculated by the Youden index), the 
sensitivity, specificity, positive-predictive values, and 
negative-predictive values were 67.9%, 73.2%, 30.5%, 
and 28.3%, respectively. In a subgroup analysis that 
included patients with tumor size larger than 2 cm 
(n = 40) and with clear-cell histology (n = 44), AUCs 
for ESM-1 levels were 0.771 and 0.721, respectively. 
Because of the older age of patients in the RCC group and 
the higher levels of serum ESM-1 in older participants, 
we performed a multivariate linear regression analysis. 
After controlling for effects of age and gender, we found 
that RCC significantly affects the serum level of ESM-1 
(P < 0.001) (Table 3).When we divided the entire cohort 
according to age, the AUCs for ESM-1 were 0.813 in the 
younger group (age ≤ 50 years) and 0.637 in the older 
group (age > 50 years). When we analyzed the serial 
change in serum ESM-1 levels, the mean ESM-1 levels 
at 1 month and 3 months after surgery were 0.56  ±  0.07 
ng/mL and 0.56  ±  0.06 ng/mL, respectively (Figure 2). 
In paired t tests, the serum ESM-1 levels at 1 month and 
3 months after surgery were significantly lower than the 
preoperative serum ESM-1 level (P = 0.047 and P = 
0.009, respectively).
DISCUSSION
In this study, we found that serum ESM-1 levels 
were higher in patients with RCC than in healthy 
individuals. Although serum ESM-1 levels were 
influenced by age, they were also promoted by the 
presence of RCC. Thus, serum ESM-1 can potentially be 
used as a diagnostic marker for RCC. 
Increased levels of ESM-1 have been found in the 
sera of patients with colorectal cancer, hepatocellular 
carcinoma, and acute leukemia [13–15]. Moreover, 
immunohistochemical studies have shown that elevated 
ESM-1 expression correlates with unfavorable prognoses 
in different types of cancers, including glioblastoma, colon 
cancer, and hepatocellular carcinoma, as well as RCC 
[12, 16–18]. Because angiogenesis is an important process 
in tumor progression, factors that are influenced by or related 
to this process can be useful for diagnostic and prognostic 
determinations. Tumor cells in RCC are characterized by 
an increased stability of hypoxia-inducible factor (HIF) 
and the subsequent induction of VEGF expression [19]. 
Rennel et al. [10] demonstrated that ESM-1 is secreted from 
endothelial cells in response to VEGF, suggesting ESM-1 
as potential tumor marker of RCC. Subsequent study has 
shown that serum ESM-1 levels increased in patients with 
RCC but not in healthy control subjects [12]. However, the 
study focused on overexpression of ESM-1 in clear cell 
RCC, and the small number of patients were included in 
the ELISA analysis. Moreover, the previous study found 
that ESM-1 levels were increased in clear cell RCC but not 
in papillary RCC, and ESM-1 immunoreactivity was very 
rare in papillary RCC cells. However, in our study, serum 
ESM-1 levels did not differ between patients with clear 
cell and non–clear cell RCC. Although activation of HIF 
and VEGF have been described mostly in clear cell RCC, 
HIF activity in other subtypes of RCC has been suggested 
[20]. Moreover, in our study, the diagnostic performance of 
ESM-1 was not improved in the clear cell RCC subgroup. 
Thus, we speculate that serum ESM-1 might serve as a 
more generalized biomarker and is not restricted to clear 
cell RCC.
In the results of the subgroup analysis, we found 
that the diagnostic performance of serum ESM-1 for RCC 
improved in patients with tumor size larger than 2 cm. It is 
attributable to the reflection of the tumor burden by serum 
ESM-1, which is in line with the previous study [12]. With 
the tumor size, the diagnostic performance was greatly 
improved in the young cohort, which included individuals 
aged 50 years or younger. The diagnostic performance of 
serum ESM-1 is notable in the young cohort. We found 
that the level of serum ESM-1 increased with age. The 
aging process is closely related to chronic inflammation, 
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which also influences the expression of ESM-1. Therefore, 
although ESM-1 levels were increased in sera from patients 
with RCC independent of age, RCC might be more difficult 
to diagnose in elderly patients by ESM-1 levels alone. 
However, evidence has shown that small renal masses, 
which are typically slow-growing nonaggressive tumors, 
might not be a factor in the survival of elderly patients [21]. 
Thus, ESM-1 levels in serum might be more useful for 
diagnosing RCC in younger patients.
The measurement of serum ESM-1 levels after 
the surgical removal of RCC was not performed in 
previous studies. We found that the levels decreased 
Table 1: Characteristics of study cohort
RCC (n = 56) Control (n = 56) P value
Age (year)
  mean ± SD 52.9 ± 12.6 48.2 ± 9.0 0.027
  median (IQR) 54 (44–62) 49 (40–57)
Gender, n (%) 1.000
  male 35 (62.5) 35 (62.5)
  female 21 (37.5) 21 (37.5)
Size (cm)
  mean ± SD 3.64 ± 3.36
  median (IQR) 2.7 (2–3.8)
Stage, n (%)
  T1a 43 (76.8)
  T1b 6 (10.7)
  T2a 2 (3.6)
  T2b 2 (3.6)
  T3a 3 (5.4)
Furmann grade, n (%)
  I–II 36 (64.3)
  III–IV 20 (35.7)
Cell type, n (%)
 clear cell 44 (78.6)
 non-clear 12 (21.4)
RCC = renal cell cancer, SD = standard deviation, IQR = interquartile range.
Table 2: Serum endocan level according to tumor characteristics in patients with RCC
serum endocan level P value serum endocan level (clear cell RCC only) P value
Tumor size (cm) 0.095 0.006
  ≤2 (n = 16) 0.56 ± 0.08 0.54 ± 0.08
  >2, ≤4 (n = 27) 0.59 ± 0.06 0.59 ± 0.06
  >4 (n = 13) 0.61 ± 0.05 0.63 ± 0.02
Stage 0.625 0.024
  T1 (n = 49) 0.59 ± 0.07 0.58 ± 0.07
  >T2 (n = 7) 0.59 ± 0.07 0.63 ± 0.02
Furmann grade 0.836 0.937
  I–II (n = 36) 0.59 ± 0.06 0.59 ± 0.06
  III–IV (n = 20) 0.58 ± 0.08 0.59 ± 0.07
Cell type 0.904
  clear cell (n = 44) 0.59 ± 0.06
  non-clear (n = 12) 0.59 ± 0.08
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postoperatively, although they remained higher than in 
the control group. We could not exclude an effect from 
the surgery itself, because postoperative serum ESM-1 
levels were not obtained from the healthy control subjects. 
Nevertheless, the differences were statistically significant 
in paired t-tests. The decreased levels were maintained for 
up to 3 months postoperatively. We believe these findings 
suggests that serum ESM-1 can be a surveillance marker 
for RCC.
Although elevated serum levels of ESM-1 in 
RCC have been reported, this study included the largest 
number of patients with RCC and healthy control subjects. 
Our results indicated that ESM-1 can be used as both a 
diagnostic and a surveillance biomarker. In addition, 
we found that ESM-1 showed improved diagnostic 
performance in a young cohort. These novel findings 
represent strengths of our study.
Some limitations of this study must be considered: 
First, this study did not include patients with benign 
renal masses. Currently, we only have a small number of 
patients with benign renal masses in our database, and a 
larger cohort is needed to investigate the efficacy of serum 
ESM-1 levels in differentiating RCC from benign renal 
masses. Second, serum ESM-1 levels are also elevated 
in other types of cancers and thus are not specific for 
RCC. However, unlike hepatocellular carcinoma and 
colorectal cancer, RCC has no serologic biomarker for 
diagnosis. Third, the prognostic ability of ESM-1 in RCC 
was not assessed in this study, because only two cases 
of recurrence were seen during the median 27 months 
of follow-up. Therefore, a longer follow-up involving 
patients with more advanced stages of RCC is required 
to evaluate the use of serum ESM-1 levels for prognosis. 
The results of our study show that serum ESM-
1 levels can serve as a diagnostic biomarker for RCC, 
particularly in patients younger than 50 years. Moreover, 
the assessment of serum ESM-1 levels can be utilized for 
monitoring patients with RCC after surgery. Although a 
validation in a larger cohort is necessary, we conclude 
that serum ESM-1 can potentially be clinically applied for 
diagnosing and monitoring RCC.
MATERIALS AND METHODS
Study participants and blood sampling
From October 2013 to March 2015, we 
prospectively enrolled patients undergoing nephrectomies 
in the urology department at Severance Hospital. In 
total, 56 patients with pathologically confirmed RCC 
underwent partial or radical nephrectomies. For the 
control group, we included 56 age-matched and sex-
matched individuals from a cohort of healthy kidney 
donors who had undergone donor nephrectomies 
during the same period. This study was approved by the 
Institutional Review Board of Severance Hospital (IRB 
no. 4-2013-0166), and informed consent was obtained 
from all participants before study enrollment.
Blood sampling was performed the day before 
surgery for all participants and at 1 month and 3 months 
after surgery for patients in the RCC group. Blood samples 
were centrifuged for 15 minutes at 1,000 × g within 
30 minutes of collection, and the sera were divided into 
aliquots and stored at −80°C for subsequent measurements 
of ESM-1 levels. 
Assessment of ESM-1 levels
In all serum samples, the level of ESM-1 was 
quantified by use of a commercially available ELISA 
kit (Lunginnov s.a.s., Lille, France). Serum was diluted 
twofold before analysis. Experiments were performed 
Figure 1: (A) Difference in serum ESM-1 level between RCC patients and control subjects. (B) ROC curve for serum ESM-1 comparing 
RCC patients (n = 56) and control subjects (n = 56). The AUC for serum ESM-1 was 0.721 (95% CI, 0.628–0.817).
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according to manufacturer’s instructions. Microwell plates 
were coated with 100 μL of capture antibody (2 μg/mL) 
and incubated overnight at 4°C. The coated plates were 
blocked with 5% skim milk in tris buffered saline (TBS) 
for 1 hour at 37°C. After a washing step with phosphate 
buffered saline (PBS), the plates were incubated with 
100 μL of serum specimen for 1 hour, and then washed 
and incubated with 100 μL of secondary antibody (diluted 
1:10,000) for 1 hour at room temperature. After the 
washing, 100 μL of streptavidin-horseradish peroxidase 
(1:10,000) was added and incubated for 30 minutes. 
After a final washing, 50 μL of tetramethylbenzidine 
substrate was added and the reaction was stopped with 
1 N H2SO4. The absorbance was determined at 450 nm 
on a spectrophotometer. All assays were performed in 
duplicate.
Statistical analysis
ESM-1 levels in the control group were compared 
according to the sex and age (≤50 years vs. >50 years) 
of the participants. Serum ESM-1 levels were then 
compared between control subjects and RCC patients, as 
well as according to tumor size, pathologic stage, Fuhrman 
grade, and histology in RCC patients. ROC curves were 
generated and the AUCs were calculated. The optimal 
cutoff value, which maximizes sensitivity and specificity, 
was obtained by use of the Youden index. In addition, we 
performed subgroup analyses of RCC patients with tumor 
sizes larger than 2 cm or with clear-cell histology. 
Although RCC and control groups were matched 
by age and sex, patients in the RCC group were older 
than those in the control group. Because of the higher 
levels of serum ESM-1 in older participants than in 
their counterparts in the control group, we performed 
multivariate linear regression analyses to evaluate whether 
the presence of RCC significantly increases the level of 
serum ESM-1. 
Preoperative and postoperative (at 1 month and 
3 months) ESM-1 levels were compared. The quantitative 
values were compared by use of Student’s t-tests or one-
way analyses of variance, whereas qualitative variables 
were compared by use of chi-square or Fisher’s exact 
tests. Statistical analyses were performed by the Statistical 
Package for Social Science for Windows, Version 
18.0 (SPSS, Chicago, IL, USA). A P-value < 0.05 was 
Figure 2: Serial changes in serum ESM-1 levels after surgery in patients with RCC. Serum ESM-1 level declined after 
surgery, and preoperative and postoperative serum ESM-1 levels were compared by use of a paired t-test.
Table 3: Multivariate linear regression analysis to evaluate whether the presence of RCC independently affects the 
level of serum ESM-1
Univariate Multivariate
β P-value β P-value
Age 0.239 0.011 0.165 0.070 
Gender –0.050 0.600 –0.035 0.693 
RCC (vs control) 0.375 <0.001 0.340 <0.001
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considered significant, and all P-values were two-sided. 
The ROC analyses and plotting graphics were performed 
by R Version 3.2.5 software (http://www.r-project.org).
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